These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16145058)

  • 1. Acting on imperfect evidence: How much regret are we ready to accept?
    Djulbegovic B; Frohlich A; Bennett CL
    J Clin Oncol; 2005 Oct; 23(28):6822-5. PubMed ID: 16145058
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
    Adams JR; Angelotta C; Bennett CL
    J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
    [No Abstract]   [Full Text] [Related]  

  • 5. Are guidelines on use of colony-stimulating factors in solid cancers flawed?
    Haines IE; Olver I
    Intern Med J; 2009 Apr; 39(4):259-62. PubMed ID: 19402867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors].
    Korman DB; Boronovskaia LE; Maslova IA; Andreeva EV; Seregina GV
    Vopr Onkol; 2008; 54(5):639-42. PubMed ID: 19069482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis.
    Wang J; An L; Chen S; Ouyang J; Zhou R; Chen B; Yang Y
    Acta Haematol; 2009; 121(4):223-6. PubMed ID: 19546524
    [No Abstract]   [Full Text] [Related]  

  • 9. Granulocyte colony-stimulating factors: finding the right indication.
    Lyman GH; Shayne M
    Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of granulocyte colony-stimulating factor in infectious diseases.
    Gaviria JM; Garrido SM; Root RK
    Curr Clin Top Infect Dis; 2001; 21():302-22. PubMed ID: 11572156
    [No Abstract]   [Full Text] [Related]  

  • 11. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Indications for the use of granulocyte growth factors].
    Elonen E
    Duodecim; 1997; 113(22):2319-25. PubMed ID: 10892137
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of adult patients with aplastic anemia in Japan].
    Urabe A; Ichiki S; Usukine K; Ijima K
    Rinsho Ketsueki; 2005 Jun; 46(6):389-93. PubMed ID: 16447719
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
    Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
    Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia.
    Mathewson KA; Lindenmayer JP
    J Clin Psychopharmacol; 2007 Dec; 27(6):714-5. PubMed ID: 18004146
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
    Khan S; Dhadda A; Fyfe D; Sundar S
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
    Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
    Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.